Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer

Cancers, Free Full-Text

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

PG545 significantly enhances overall survival in a mastectomy model of

Frontiers The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality

PG545 inhibits primary tumor growth and metastasis. A, orthotopic Pan02

Visual Abstract

Frontiers Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more

Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer - ScienceDirect

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer - ScienceDirect